ArticleFrontiers in public health2026
A three-phase epidemiological fluctuation framework of extrapulmonary tuberculosis in Fuyang, China: a retrospective study.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study characterized eight-year epidemiological and clinical features, diagnostic performance, and drug resistance of EPTB in Fuyang, China, and proposed a framework to interpret its dynamic burden. Methods: We conducted a retrospective study of EPTB patients at Fuyang Second People's Hospital from January 2018 to December 2025. Demographic, clinical, and laboratory data were extracted from medical records. Descriptive statistics and chi-square tests were used to analyze epidemiological characteristics. Diagnostic yields of IGRA, GeneXpert MTB/RIF Ultra, and culture were compared based on positivity rates. Drug susceptibility testing (DST) was performed on culture-positive isolates. MDR was defined as resistance to at least isoniazid and rifampicin. Results: EPTB accounted for 28.46% (2,281/8015) of all tuberculosis (TB) cases. The majority of patients were aged (≥50 years, 52.78%), male (70.45%), and farmers (70.50%). Temporal analysis revealed a distinctive fluctuation pattern, with EPTB cases predominantly concentrated in 2019-2021 and 2024, which we interpret as reflecting a three-phase fluctuation framework. The most prevalent subtypes of EPTB were pleural TB (60.50%), osteoarticular TB (12.98%), lymphatic TB (6.97%), central nervous system (4.65%), and gastrointestinal TB (3.24%). IGRA showed the highest positivity rate (88.04%), significantly higher than GeneXpert MTB/RIF Ultra (35.60%) and culture (14.53%) ( Conclusion: EPTB constitutes a significant burden, particularly among aged, male, and farming populations. Pleural TB is the most common form, and IGRA offers superior detection yield. Notably, the 2018-2025 EPTB proportion fluctuations fit a three-phase descriptive framework (diagnosis-driven ascendancy, pandemic disruption, re-equilibration), inspired by Omran's theory as a heuristic analogy, with breakpoints based on annual trends rather than statistically derived. Although overall drug resistance was low among the tested isolates, the presence of MDR cases in this selected sample underscores the importance of routine DST; however, larger unselected studies are warranted to validate the true population-level MDR burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.